Affiliation:
1. Tehran University of Medical Sciences
2. National Nutrition and Food Technology Research Institute, Shahid Behehshti University of Medical Sciences Tehran
Abstract
Abstract
Background: There is evidence of the occurrence of headache after vaccination against COVID-19. However, only a few studies have examined the headache characteristics and related determinants, especially among healthcare workers with a history of COVID-19 infection.
Methods: We evaluated the incidence of headaches after injection of different types of COVID-19 vaccine to determine factors relating to the incidence of headache after vaccination among the Iranian healthcare workers who had previously contracted COVID-19. A group of 334 healthcare workers with a history of COVID-19 infection were included and vaccinated (at least one month after recovery without any COVID-19 related symptoms) with different COVID-19 vaccines. The baseline information, headache characteristics and vaccine specifications were recorded.
Results: Overall, 39.2% reported experiencing a post-vaccination headache. Of those with a previous history of headache, 51.1% reported migraine-type, 27.4% tension-type and 21.5% other types. The mean time between vaccination and headache appearance was 26.78±6.93 h, with the headache appearing less than 24 h after vaccination in most patients (83.2%). The headaches reached its peak within 8.62±2.41 hours. Most patients reported a compression-type headache. The prevalence of post-vaccination headaches was significantly different according to the type of vaccine used. The highest rates were reported for AstraZeneca, followed by Sputnik V. In regression analysis, the vaccine brand, female gender and initial COVID-19 severity were the main determinants for predicting post-vaccination headache.
Conclusion: Participants commonly experienced a headache following vaccination against COVID-19. Our study results indicated that this was slightly more common in females and in those with a history of severe COVID-19 infection.
Publisher
Research Square Platform LLC
Reference42 articles.
1. Ghasemiyeh P, Mohammadi-Samani S, Firouzabadi N, Dehshahri A, Vazin A. A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines.Int Immunopharmacol. 2021 Sep17;100:108162. doi: 10.1016/j.intimp.2021.108162. Online ahead of print.
2. SARS-CoV-2 new variants: Characteristic features and impact on the efficacy of different vaccines;Khan A;Biomed Pharmacother
3. COVID-19 vaccination: evidence of waning immunity is overstated;Scott J;BMJ
4. Gómez-Carballa A, Pardo-Seco J, Bello X, Martinón-Torres F, Salas A. Superspreading in the emergence of COVID-19 variants. Trends Genet. 2021 Sep 8:S0168-9525(21)00262-6. doi: 10.1016/j.tig.2021.09.003. Online ahead of print.
5. Mehraeen E, Dadras O, Afsahi AM, Karimi A, MohsseniPour M, Mirzapour P, Barzegary A, Behnezhad F, Habibi P, Salehi MA, Vahedi F, Heydari M, Kianzad S, Moradmand-Badie B, Javaherian M, SeyedAlinaghi S, Sabatier JM. Vaccines for COVID-19: A Review of Feasibility and Effectiveness. Infect Disord Drug Targets. 2021 Sep 23. doi: 10.2174/1871526521666210923144837.